BrainCheck, a Houston, Texas-based digital neurocognitive testing platform company announced it has raised $1.5 million in additional capital to bring artificial intelligence and personalized medicine to dementia care through its cognitive care management technology known as BrainCheck Care.
This round of funding was led by True Wealth Ventures. Tensility Venture Partners, XFactor Ventures, S3 Ventures, and several angel investors participated in this round as well. Braincheck has raised $6 million in total funding to date.
With this funding round, the company is planning to expand its research and development efforts and enhance its offering in the dementia space. Plus the company is going to invest in sales and marketing talent to accelerate deployment in clinical practice.
BrainCheck Care offers a combination of assessments, screeners, workflows, and clinical decision support algorithms for physicians to use in providing personalized care plans to patients and caregivers at the point of care.
“BrainCheck’s rich and robust dataset on cognitive health, paired with other health and biometric data, enable us to personalize dementia care at scale,” said BrainCheck founder and CEO Dr. Yael Katz. “For the first time, clinicians and caregivers can observe whether interventions are working by tracing cognitive change to a patient’s medications, chronic diseases, or lifestyle, and iterate on these interventions to optimize outcomes.”
The BrainCheck platform enables physicians to rapidly and accurately assess cognitive functions and delivers cognitive care at scale. And it is currently used by hundreds of clinical practices and over 40,000 individuals. As it is one of the first to market with an end-to-end cognitive health solution, BrainCheck is positioned to change millions of lives by providing a promising solution for the “silver tsunami,” a metaphor used for describing the aging population.
“We saw a great opportunity with BrainCheck,” added Tensility Venture Partners managing director and co-founder Armando Pauker. “They’re sitting on a treasure trove of difficult-to-obtain data and are addressing a large market opportunity. They bring the power and benefits of AI into clinical care to make cognitive testing easily available to all.”
Currently, there are 5.7 million people who are suffering from dementia in the U.S. according to the Alzheimer’s Association. And new research from The Lancet Commission shows that one-third of dementia cases are preventable. Plus disease progression can be slowed through effective detection and addressing modifiable risk factors.
“The research is clear and it has now been clinically proven that patients can delay the onset of dementia,” explained S3 Ventures partner Charlie Plauche. ”By helping physicians detect this debilitating disease early, BrainCheck’s platform technology will improve the lives of millions in the coming years.”
BrainCheck is currently headquartered at the Texas Medical Center Innovation Institute known as TMCx. And the company recently opened a second location in Austin, Texas.
And BrainCheck was founded in 2015 by both Dr. David Eagleman and Dr. Yael Katz. BrainCheck was conceptualized at the Eagleman Neuroscience Laboratory at the Baylor College of Medicine (now Stanford).